Cholinesterase inhibitor use is associated with cognitive benefits that are modest but persist over time, according to new findings from a large registry study.
Researchers from the Karolinska University Hospital and Karolinska Institutet, in Huddinge, Sweden, analyzed longitudinal data from the Swedish Dementia Registry to investigate whether cholinesterase inhibitors are associated with less cognitive decline in AD and a reduced risk of severe dementia or death.
The study population comprised 11,652 AD patients who were started on a cholinesterase inhibitor within 3 months of being diagnosed with dementia, and 5,826 matched non-treated patients.
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.